Does the media refer more to ADMA or ACAD?

In the previous week, ADMA Biologics had 26 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 32 mentions for ADMA Biologics and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat ADMA Biologics' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADMA or ALLO?

In the previous week, ADMA Biologics had 29 more articles in the media than Allogene Therapeutics. MarketBeat recorded 32 mentions for ADMA Biologics and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.53 beat ADMA Biologics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ADMA or PCVX?

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ADMA Biologics $509.86M 3.98 $146.93M $0.68 12.87 Vaxcyte N/A N/A -$766.63M -$6.88 N/A

Is ADMA or PCVX more profitable?

ADMA Biologics has a net margin of 32.43% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets ADMA Biologics 32.43% 39.98% 28.08% Vaxcyte N/A -32.51% -29.51%

Does the media favor ADMA or PCVX?

In the previous week, ADMA Biologics had 27 more articles in the media than Vaxcyte. MarketBeat recorded 32 mentions for ADMA Biologics and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.90 beat ADMA Biologics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APGE or ADMA?

In the previous week, ADMA Biologics had 27 more articles in the media than Apogee Therapeutics. MarketBeat recorded 32 mentions for ADMA Biologics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat ADMA Biologics' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADMA or IMVT?

In the previous week, ADMA Biologics had 28 more articles in the media than Immunovant. MarketBeat recorded 32 mentions for ADMA Biologics and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat ADMA Biologics' score of 0.00 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 0 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADMA Biologics (ADMA) Competitors

$8.75 +0.04 (+0.46%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$8.71 -0.04 (-0.50%)

As of 04:30 AM Eastern

Compare

ADMA vs. ACAD, ALLO, PCVX, APGE, and IMVT

Should you buy ADMA Biologics stock or one of its competitors? MarketBeat compares ADMA Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Vaxcyte (PCVX), Apogee Therapeutics (APGE), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ADMA Biologics (NASDAQ:ADMA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.98	$146.93M	$0.68	12.87
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

ADMA Biologics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, ADMA Biologics had 26 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 32 mentions for ADMA Biologics and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat ADMA Biologics' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics currently has a consensus price target of $18.67, indicating a potential upside of 113.33%. ACADIA Pharmaceuticals has a consensus price target of $32.94, indicating a potential upside of 31.29%. Given ADMA Biologics' higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

ACADIA Pharmaceuticals has a net margin of 34.30% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, ADMA Biologics had 29 more articles in the media than Allogene Therapeutics. MarketBeat recorded 32 mentions for ADMA Biologics and 3 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.53 beat ADMA Biologics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

ADMA Biologics has a net margin of 32.43% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Allogene Therapeutics	N/A	-56.45%	-40.36%

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.98	$146.93M	$0.68	12.87
Allogene Therapeutics	$20K	30,545.78	-$190.89M	-$0.77	N/A

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics currently has a consensus target price of $18.67, indicating a potential upside of 113.33%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 381.48%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Vaxcyte?

ADMA Biologics (NASDAQ:ADMA) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

ADMA Biologics has a net margin of 32.43% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Vaxcyte	N/A	-32.51%	-29.51%

ADMA Biologics has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.98	$146.93M	$0.68	12.87
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

ADMA Biologics presently has a consensus target price of $18.67, indicating a potential upside of 113.33%. Vaxcyte has a consensus target price of $86.00, indicating a potential upside of 54.95%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ADMA Biologics had 27 more articles in the media than Vaxcyte. MarketBeat recorded 32 mentions for ADMA Biologics and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.90 beat ADMA Biologics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Vaxcyte on 11 of the 15 factors compared between the two stocks.

How does ADMA Biologics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

ADMA Biologics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
ADMA Biologics	$509.86M	3.98	$146.93M	$0.68	12.87

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 3.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Apogee Therapeutics currently has a consensus target price of $121.25, suggesting a potential downside of 9.61%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 113.33%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ADMA Biologics had 27 more articles in the media than Apogee Therapeutics. MarketBeat recorded 32 mentions for ADMA Biologics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat ADMA Biologics' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a net margin of 32.43% compared to Apogee Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
ADMA Biologics	32.43%	39.98%	28.08%

Apogee Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Summary

ADMA Biologics beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Immunovant?

ADMA Biologics (NASDAQ:ADMA) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

ADMA Biologics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.98	$146.93M	$0.68	12.87
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

ADMA Biologics has a net margin of 32.43% compared to Immunovant's net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Immunovant	N/A	-65.66%	-59.88%

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ADMA Biologics presently has a consensus price target of $18.67, suggesting a potential upside of 113.33%. Immunovant has a consensus price target of $39.70, suggesting a potential downside of 0.55%. Given ADMA Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

ADMA Biologics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, ADMA Biologics had 28 more articles in the media than Immunovant. MarketBeat recorded 32 mentions for ADMA Biologics and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat ADMA Biologics' score of 0.00 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Immunovant on 12 of the 15 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.02B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	12.87	20.49	27.07	23.94
Price / Sales	3.98	300.33	515.91	90.33
Price / Cash	13.31	60.31	26.68	47.25
Price / Book	4.35	7.92	10.43	6.14
Net Income	$146.93M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.35%	-1.09%	-1.20%	-1.82%
1 Month Performance	5.29%	2.56%	1.12%	-1.45%
1 Year Performance	-48.92%	42.16%	23.66%	16.32%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	4.2948 of 5 stars	$8.75 +0.5%	$18.67 +113.3%	-47.7%	$2.02B	$509.86M	12.87	530	Trending News
ACAD ACADIA Pharmaceuticals	4.7931 of 5 stars	$25.50 -2.7%	$32.94 +29.2%	+11.2%	$4.49B	$1.07B	11.59	510
ALLO Allogene Therapeutics	1.9258 of 5 stars	$1.93 -3.5%	$8.52 +341.6%	+41.6%	$690.31M	$20K	N/A	310
PCVX Vaxcyte	2.6865 of 5 stars	$57.03 -2.0%	$86.00 +50.8%	+53.3%	$8.41B	N/A	N/A	160
APGE Apogee Therapeutics	1.9141 of 5 stars	$133.82 +0.1%	$121.25 -9.4%	+241.3%	$8.27B	N/A	N/A	91	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, APGE, and IMVT

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Vaxcyte?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Summary

How does ADMA Biologics compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, APGE, and IMVT

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Which has better valuation and earnings, ADMA or ACAD?

Which has more risk & volatility, ADMA or ACAD?

Does the media refer more to ADMA or ACAD?

Do analysts rate ADMA or ACAD?

Is ADMA or ACAD more profitable?

Do institutionals and insiders have more ownership in ADMA or ACAD?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Does the media prefer ADMA or ALLO?

Which has more volatility and risk, ADMA or ALLO?

Is ADMA or ALLO more profitable?

Which has stronger earnings & valuation, ADMA or ALLO?

Do institutionals and insiders believe in ADMA or ALLO?

Do analysts recommend ADMA or ALLO?

Summary

How does ADMA Biologics compare to Vaxcyte?

Is ADMA or PCVX more profitable?

Which has more risk and volatility, ADMA or PCVX?

Which has stronger valuation and earnings, ADMA or PCVX?

Do analysts recommend ADMA or PCVX?

Do institutionals & insiders have more ownership in ADMA or PCVX?

Does the media favor ADMA or PCVX?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Which has stronger earnings and valuation, APGE or ADMA?

Do institutionals & insiders believe in APGE or ADMA?

Do analysts rate APGE or ADMA?

Does the media prefer APGE or ADMA?

Is APGE or ADMA more profitable?

Which has more volatility and risk, APGE or ADMA?

Summary

How does ADMA Biologics compare to Immunovant?

Which has stronger earnings & valuation, ADMA or IMVT?

Is ADMA or IMVT more profitable?

Do institutionals & insiders hold more shares of ADMA or IMVT?

Do analysts rate ADMA or IMVT?

Which has more risk and volatility, ADMA or IMVT?

Does the media refer more to ADMA or IMVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools